Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3Synovial Cyst 1Spondylosis 1Spondylolisthesis 1Spinal Stenosis 1Radiculopathy 1Pilonidal Sinus 1Neoplasms 1Musculoskeletal Diseases 1Malignant Neoplasms of Male Genital Organs 1Intervertebral Disc Displacement 1Intervertebral Disc Degeneration 1Hot Flashes 1Carcinoma, Renal Cell 1Agnosia 1

Interventions

Nivolumab 74Sunitinib 73pembrolizumab 49Everolimus 39Sorafenib 36Bevacizumab 36Axitinib 36cabozantinib 35Radiosurgery 33Ipilimumab 33pazopanib 32Magnetic Resonance Spectroscopy 27Interleukin-2 27aldesleukin 23Specimen Handling 22Cyclophosphamide 21lenvatinib 20fludarabine phosphate 17Radiotherapy 16Interferon-alpha 15Peripheral Blood Stem Cell Transplantation 14Gemcitabine 14Biopsy 14temsirolimus 13Nephrectomy 13durvalumab 11Immunohistochemistry 11CTLA-4 Antigen 11Blood Specimen Collection 11Capecitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Renal Cell × Clonidine × Clear all
NCT07092566 2026-01-20

R.E.C.K vs Exparel in Robotic Nephrectomy

Wake Forest University Health Sciences

Phase 3 Recruiting
170 enrolled
Genitourinary

Agnosia, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡